Y. Y. Polyakov, E. Baryakh, E. Misyurina, E. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Y. Smolyarchuk, T. Tolstykh, T. S. Chudnova, D. D. Ivanova, O. Kochneva, D. V. Lebedev, A. U. Abueva, A. M. Chistov, E. Zotina, I. Samsonova, M. A. Lysenko
{"title":"评估原发性中枢神经系统大 B 细胞淋巴瘤患者对 SARS-CoV-2 的体液免疫反应，发现新冠状病毒感染持续存在","authors":"Y. Y. Polyakov, E. Baryakh, E. Misyurina, E. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Y. Smolyarchuk, T. Tolstykh, T. S. Chudnova, D. D. Ivanova, O. Kochneva, D. V. Lebedev, A. U. Abueva, A. M. Chistov, E. Zotina, I. Samsonova, M. A. Lysenko","doi":"10.17650/1818-8346-2024-19-2-101-108","DOIUrl":null,"url":null,"abstract":"Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.","PeriodicalId":518071,"journal":{"name":"Oncohematology","volume":"104 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2\",\"authors\":\"Y. Y. Polyakov, E. Baryakh, E. Misyurina, E. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Y. Smolyarchuk, T. Tolstykh, T. S. Chudnova, D. D. Ivanova, O. Kochneva, D. V. Lebedev, A. U. Abueva, A. M. Chistov, E. Zotina, I. Samsonova, M. A. Lysenko\",\"doi\":\"10.17650/1818-8346-2024-19-2-101-108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.\",\"PeriodicalId\":518071,\"journal\":{\"name\":\"Oncohematology\",\"volume\":\"104 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncohematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1818-8346-2024-19-2-101-108\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncohematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1818-8346-2024-19-2-101-108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
